CompletedPhase 1NCT03253289

Meclizine for Hepatocellular Carcinoma

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tannaz Armaghnay
Principal Investigator
Tannaz Armaghany, MD
Baylor College of Medicine
Intervention
Meclizine Oral Tablet(drug)
Enrollment
13 target
Eligibility
18 years · All sexes
Timeline
20172023

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03253289 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials